Biosergen

Biosergen OCF Margin

The Operating Cash Flow Margin of Biosergen (BIOSGN.ST) as of Oct 18, 2026 is -440.32 %. In the previous year, Operating Cash Flow Margin was -103.43 % — a change of 325.72% (lower).

OCF Margin

-440.32 %

YoY

325.72%

Last updated:

Operating Cash Flow Margin of Biosergen is 2021 -440.32 % . Operating Cash Flow Margin of Biosergen was 2020 -103.43 % . It decreases by 325.72% lower compared to the previous year.

The Biosergen OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2019
-176.14 SEK
Jan 1, 2020
-103.43 SEK
Jan 1, 2021
-440.32 SEK
The Biosergen OCF Margin history
YEAROCF MarginYoY
-440.32 %+325.72%
-103.43 %-41.28%
-176.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biosergen Stock analysis

What does Biosergen do? Biosergen AB is a biopharmaceutical company headquartered in Solna, Sweden. The company went public on June 24, 2021, with its ticker symbol BIOSGN.ST and ISIN SE0026821852. Biosergen AB conducts biopharmaceutical research and development through its subsidiary Biosergen AS, utilizing laboratory facilities in Trondheim, Norway, and other global locations. The company is focused on developing BSG005, an antifungal drug that has shown safety and potency benefits compared to existing treatments. BSG005 is designed to address invasive fungal infections affecting immune-compromised patients, including those with AIDS, cancer, or who have undergone transplants. At equivalent doses, BSG005 has demonstrated a three- to fourfold higher potency against targeted fungal strains than current standard treatments, while avoiding the kidney toxicity associated with other drugs in its class. Biosergen AB operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is biosergen.net, providing further information about its research and development activities. The firm's primary focus remains on advancing BSG005 through clinical development, targeting a significant unmet medical need in the treatment of fungal infections among vulnerable patient populations. Biosergen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biosergen stock

Operating Cash Flow Margin of Biosergen is -440.32 % in 2021.

Operating Cash Flow Margin of Biosergen changed from -103.43 % to -440.32 %, representing a 325.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Biosergen since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Biosergen with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biosergen

All Key Metrics — Biosergen